ARCHIVES

ASCO: Anastrozole Adds Treatment Option, But Tamoxifen Remains Standard

This article is from The Cancer Letter archive.

Vol. 28 No. 33 | September 13, 2002

Download PDF Visit The Full Archive

Related Articles

MGI Pharma’s Irofulven In Phase III Trial Vs. 5-FU For Advanced Pancreatic Cancer.

March 2, 2001

In Brief: Oldham To Head Biological Response Modifiers Program; Walter, Namovicz Named Acting Heads

August 8, 1980

Decision On Status Of Frederickson, DeVita Due In Month, Schweiker Says

May 1, 1981

NCI Agrees To Offer New Screening RFP In The Future

May 28, 1976

Zerhouni Appoints Kington As Deputy Director

February 14, 2003

Sen. Arlen Specter Remembered as Champion Of Federal Biomedical Resesarch Funding

October 19, 2012